What We Do


NVP is advancing a new generation of Targeted Nanosphere (TNS) based products incorporating our core and highly optimized HPLN (Hybrid Polymerized Liposomal Nanoparticle) IP technology. These TNS may provide a vast improvement in flexibility and choice for patients restricted by current treatment options including antibody, immunotherapy and ADC based products. Both by repositioning existing therapies such as chemotherapeutics and by truly targeting and optimising the delivery of emerging candidates including small molecules and nucleic acid based therapeutics.

Our current main candidate focus is in oncology with our lead candidate NV103 approaching pediatric (Ewing Sarcoma) and adult (Glioblastoma) IND status, but it is already clear that once clinically validated TNS technology can be applied to other oncology challenges such as pancreatic and liver cancer plus other non-oncological sectors such as neurology, as opportunities present. We also have other candidates such as NV101, NV102 and NV201 plus a rapidly progressing pilot programs in nucleic acid delivery and in trans-BBB (blood brain barrier) related delivery therapy.

Our Technology

NVP is using HPLN as a base entity to obtain an advanced, targeted nanosphere (TNS) based approach able to significantly reposition and enhance existing cancer therapies.

This is because HPLN provides a unique new nanoparticle encapsulating platform designed to harness and enable genuine targeting to tumor and other specific cell surface antigens. Also, unlike other targeted technologies, the ‘payload’ incorporated into HPLN, enabling powerful targeted nanospheres (TNS), can be more easily user selected, including proven cytotoxics, nucleic acid based entities or small molecules, or even any mixture thereof. HPLN technology is subject to broad patent control by NVP.

HPLN and the resultant TNS candidates already promise to serve as an important new, effective and safe drug delivery platform to initially treat Glioblastoma, Ewing sarcoma and human adult leukemia as well as other CD99 or CD19 based tumors, via our own in-house candidates and beyond via collaborative programs. The technology is widely applicable to use with other targeting species, including bispecific targeting, other malignancies, therapeutic or even diagnostic opportunities as further candidate options develop.

Why is HPLN and the TNS approach unique?


We already have excellent chemotherapeutic compounds and rich knowledge in their everyday use, plus emerging tumor-specific biologicals. However, the key issues that our approach can clearly address include:

– Improving both efficacy and capability of existing agents in existing settings

– Improving applicability of existing drugs to ‘new cancers’

– Improving management of toxicity

– Improving scheduling practicalities with treatments

– Developing innovative or enhanced methods of delivering potential new entities or treatments via TNS either in oncology or other therapeutic areas